Paratus Sciences presented preclinical data for PS-1001, a first-in-class pan-inflammasome inhibitor designed to block release of IL-1β and IL-18, cytokines implicated in autoinflammatory skin disorders. The company characterized PS-1001’s mechanism and preclinical profile in models relevant to hidradenitis suppurativa. If the compound advances to clinical testing, it would represent a new approach targeting upstream inflammasome activation rather than downstream cytokines. Sponsors and clinicians should watch for safety and target-engagement readouts in planned translational studies.